title: Analysis of reasons for not implementing pathogen inactivation for platelet concentrates.
abstract: In the last 10 years three technologies capable of inactivating pathogens in platelet concentrates have been authorized in Europe although only one based on the addition of amotosalen and illumination with ultraviolet A (UVA) light, has been approved by the National Agency for the Safety of Medicines and Health Products (ANSM). An intense debate exists about the implementation of pathogen inactivation technologies for labile blood components in general and for platelet concentrates in particular. In this review, we will analyze some of the most frequently argued reasons for not implementing pathogen inactivation for platelet components, i.e.: current platelet components are safe enough; pathogen inactivation technologies might be toxic for the recipient; and pathogen inactivation technologies affect platelet function and increase the risk of bleeding. The analysis and discussion of the evidence currently available to answer those reservations will be limited to the pathogen inactivation technology based on amotosalen and UVA.
authors.affiliation: Department of Hemotherapy and Hemostasis, Biomedical Diagnostic Center, University Clinic Hospital, Agustí Pi i Sunyé Biomedical Research Institute (IDIBAPS), Villarroel 170, 08036 Barcelona, Spain. mlozano@clinic.ub.es
authors.forename: M
authors.initials: M
authors.lastname: Lozano
authors.forename: J
authors.initials: J
authors.lastname: Cid
mesh_terms: D016470:Bacteremia / Q000517:prevention & control / Q000635:transmission; D001792:Blood Platelets / Q000187:drug effects / Q000382:microbiology* / Q000528:radiation effects / Q000821:virology*; D058731:Blood Safety / Q000592:standards; D017848:Blood-Borne Pathogens / Q000187:drug effects / Q000528:radiation effects; D011564:Furocoumarins / Q000494:pharmacology; D006470:Hemorrhage / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D050296:Microbial Viability; D015337:Multicenter Studies as Topic; D010777:Photochemistry; D017319:Photosensitizing Agents / Q000494:pharmacology; D015539:Platelet Activation / Q000187:drug effects / Q000528:radiation effects; D017713:Platelet Transfusion / Q000009:adverse effects / Q000379:methods; D010983:Plateletpheresis; D016032:Randomized Controlled Trials as Topic; D014466:Ultraviolet Rays; D014766:Viremia / Q000517:prevention & control / Q000635:transmission
chemical_list: D011564:Furocoumarins; D017319:Photosensitizing Agents; C118577:amotosalen